Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rezpegaldesleukin by Nektar Therapeutics for Alopecia Areata: Likelihood of Approval
Rezpegaldesleukin is under clinical development by Nektar Therapeutics and currently in Phase II for Alopecia Areata. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...
NKTR-255 by Nektar Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
NKTR-255 by Nektar Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
NKTR-255 by Nektar Therapeutics for Colon Carcinoma: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Colon Carcinoma. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Anal Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Anal Cancer. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Cervical Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
NKTR-255 by Nektar Therapeutics for Solid Tumor: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Colon Carcinoma: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Colon Carcinoma. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Anal Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Anal Cancer. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Cervical Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
NKTR-255 by Nektar Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
NKTR-255 by Nektar Therapeutics for Solid Tumor: Likelihood of Approval
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Nektar Therapeutics gets grant for cancer treatment using 4-1bb and il-2rß agonists
Nektar Therapeutics has been granted a patent for a method of cancer treatment involving the administration of a 4-1BB agonist...
Nektar Therapeutics files patent for conjugate of water-soluble polymer and factor viii for administration
Nektar Therapeutics has filed a patent for conjugates that involve attaching a water-soluble polymer to a Factor VIII moiety through...